ITMI971190A0 - - Google Patents

Info

Publication number
ITMI971190A0
ITMI971190A0 ITMI971190A ITMI971190A ITMI971190A0 IT MI971190 A0 ITMI971190 A0 IT MI971190A0 IT MI971190 A ITMI971190 A IT MI971190A IT MI971190 A ITMI971190 A IT MI971190A IT MI971190 A0 ITMI971190 A0 IT MI971190A0
Authority
IT
Italy
Application number
ITMI971190A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITMI971190A0 publication Critical patent/ITMI971190A0/it
Priority to IT97MI001190A priority Critical patent/IT1291372B1/it
Priority to JP54991798A priority patent/JP2002502370A/ja
Priority to EP98924313A priority patent/EP0983068B1/en
Priority to CN98805120A priority patent/CN1255854A/zh
Priority to AU76546/98A priority patent/AU740475B2/en
Priority to PCT/EP1998/002852 priority patent/WO1998052568A1/en
Priority to AT98924313T priority patent/ATE209492T1/de
Priority to DE69802679T priority patent/DE69802679D1/de
Priority to CA002289847A priority patent/CA2289847A1/en
Publication of ITMI971190A1 publication Critical patent/ITMI971190A1/it
Application granted granted Critical
Publication of IT1291372B1 publication Critical patent/IT1291372B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IT97MI001190A 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie IT1291372B1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU76546/98A AU740475B2 (en) 1997-05-21 1998-05-14 The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances
EP98924313A EP0983068B1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO 1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
CN98805120A CN1255854A (zh) 1997-05-21 1998-05-14 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途
JP54991798A JP2002502370A (ja) 1997-05-21 1998-05-14 脳血管障害の処置に有用な薬剤の調製のための１，２，４−トリアゾロ［１，５−ｃ］ピリミジン複素環アナログの使用
PCT/EP1998/002852 WO1998052568A1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
AT98924313T ATE209492T1 (de) 1997-05-21 1998-05-14 Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
DE69802679T DE69802679D1 (de) 1997-05-21 1998-05-14 Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
CA002289847A CA2289847A1 (en) 1997-05-21 1998-05-14 The use of 1,2,4-triazolo[1,5-c]pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie

Publications (3)

Publication Number Publication Date
ITMI971190A0 true ITMI971190A0 (it) 1997-05-21
ITMI971190A1 ITMI971190A1 (it) 1998-11-21
IT1291372B1 IT1291372B1 (it) 1999-01-07

Family

ID=11377184

Family Applications (1)

Application Number Title Priority Date Filing Date
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie

Country Status (9)

Country Link
EP (1) EP0983068B1 (it)
JP (1) JP2002502370A (it)
CN (1) CN1255854A (it)
AT (1) ATE209492T1 (it)
AU (1) AU740475B2 (it)
CA (1) CA2289847A1 (it)
DE (1) DE69802679D1 (it)
IT (1) IT1291372B1 (it)
WO (1) WO1998052568A1 (it)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2315053C2 (ru) * 2000-05-26 2008-01-20 Шеринг Корпорейшн ПРОИЗВОДНЫЕ 5-АМИНО-ПИРАЗОЛО-[4,3-е]-1,2,4-ТРИАЗОЛО[1,5-с]ПИРИМИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ПРИМЕНЕНИЕ И СПОСОБЫ ПОЛУЧЕНИЯ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
JPWO2003028732A1 (ja) * 2001-09-28 2005-01-13 協和醗酵工業株式会社 受容体拮抗剤
AU2002340184B2 (en) * 2001-10-15 2005-10-06 Schering Corporation Imidazo (4,3-E)-1,2,4-triazolo(1,5-C) pyrimidines as adenosine A2A receptor antagonists
EP1448565B1 (en) 2001-11-30 2009-12-30 Schering Corporation ADENOSINE A2a RECEPTOR ANTAGONISTS
EP1453836B1 (en) 2001-11-30 2007-03-28 Schering Corporation BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
ATE432282T1 (de) 2003-04-23 2009-06-15 Schering Corp 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
AU2005236059B2 (en) 2004-04-21 2009-01-15 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
JP2009508871A (ja) 2005-09-19 2009-03-05 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとしての２−ヘテロアリール−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジン
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2023729B1 (en) 2006-06-06 2016-05-04 Intra-Cellular Therapies, Inc. Organic compounds
EP2081431B1 (en) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
CN104370922A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
JP2011528363A (ja) * 2008-07-16 2011-11-17 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アテローム性動脈硬化症の治療
PE20120120A1 (es) 2008-12-06 2012-03-03 Intra Cellular Therapies Inc DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
EP2367428B1 (en) 2008-12-06 2016-04-06 Intra-Cellular Therapies, Inc. Organic compounds
PE20120209A1 (es) 2008-12-06 2012-03-18 Intra Cellular Therapies Inc DERIVADOS DE IMIDAZO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA O PIRIMIDO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
PE20110944A1 (es) 2008-12-06 2012-01-25 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
US8536159B2 (en) 2008-12-06 2013-09-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2010065148A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE 1 INHIBITOR FOR OPHTHALMIC DISORDERS
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
ES2836129T3 (es) 2013-03-15 2021-06-24 Intra Cellular Therapies Inc Compuestos orgánicos
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
TWI686394B (zh) 2014-08-07 2020-03-01 美商內胞醫療公司 有機化合物
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
EP3220910B1 (en) 2014-11-18 2020-01-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
CN107205999B (zh) 2014-12-06 2021-08-03 细胞内治疗公司 有机化合物
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
US10688082B2 (en) 2015-06-11 2020-06-23 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
WO2019118313A1 (en) 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
CN111072676B (zh) * 2019-12-12 2021-07-16 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途

Also Published As

Publication number Publication date
CA2289847A1 (en) 1998-11-26
EP0983068A1 (en) 2000-03-08
DE69802679D1 (de) 2002-01-10
AU740475B2 (en) 2001-11-08
AU7654698A (en) 1998-12-11
JP2002502370A (ja) 2002-01-22
ITMI971190A1 (it) 1998-11-21
EP0983068B1 (en) 2001-11-28
IT1291372B1 (it) 1999-01-07
WO1998052568A1 (en) 1998-11-26
ATE209492T1 (de) 2001-12-15
CN1255854A (zh) 2000-06-07

Similar Documents

Publication Publication Date Title
ITMI971190A0 (it)
ITMI971039A0 (it)
IN183722B (it)
ITME970012A0 (it)
ITCT970017A0 (it)
ITRM970343A0 (it)
IN190855B (it)
IN185768B (it)
ITMI971308A0 (it)
CN3058057S (it)
CN3057614S (it)
CN3062610S (it)
CN3059549S (it)
CN3059396S (it)
CN3059079S (it)
CN3056826S (it)
CN3058984S (it)
CN3058923S (it)
CN3058533S (it)
CN3058531S (it)
CN3058462S (it)
CN3058320S (it)
CN3058162S (it)
CN3058088S (it)
CN3056875S (it)

Legal Events

Date Code Title Description
0001 Granted